

and/or comprises at least one of tectorigenin and tectorigenin glycoside, with the proviso that the medicament does not comprise Belamcandra chinensis extract if the medicament is used for treating a peri-menopausal or post-menopausal disorder.

18. (Amended) A method according to claim 17, wherein the extract is a Belamcandra chinensis extract.

19. A method according to claim 17, wherein the extract comprises at least one of tectorigenin and tectorigenin glycoside.

20. A method according to claim 17, wherein the extract is enriched with at least one of tectorigenin and tectorigenin glycoside.

21. A method according to claim 17, wherein the production of the estrogen-type effect comprises treatment and/or prophylaxis of a cardiovascular disease.

22. A method according to claim 21, wherein the cardiovascular disease is atherosclerosis.

23. A method according to claim 17, wherein the production of the estrogen-type effect comprises treatment and/or prophylaxis of osteoporosis.

24. A method according to claim 17, wherein the production of the estrogen-type effect comprises treatment and/or prophylaxis of a climacteric disorder.

25. A method according to claim 17, wherein the production of the estrogen-type effect comprises preventing or alleviating hot flushes.

26. (New) A method according to claim 17, wherein the extract is produced with an organic solvent or supercritical CO₂.